Comparing of Light Transmittance Aggregometry and Modified Thrombelastograph in Predicting Clinical Outcomes in Chinese Patients Undergoing Coronary Stenting with Clopidogrel
查看参考文献27篇
文摘
|
Background: Several platelet function tests are currently used to measure responsiveness to antiplatelet therapy. This study was to compare two tests, light transmittance aggregometry (LTA) and modified thrombelastography (mTEG), for predicting clinical outcomes in Chinese patients after percutaneous coronary intervention (PCI). Methods: Prospective, observational, single-center study of 789 Chinese patients undergoing PCI was enrolled. This study was investigated the correlations between the two tests and performed receiver operating characteristic curve (ROC) analysis for major adverse cardiovascular events (MACEs) at 1-year follow-up. Results: MACEs occurred in 32 patients (4.1%). Correlations were well between the two tests in the adenosine diphosphate induced platelet reactivity (Spearman r = 0.733, P< 0.001). ROC-curve analysis demonstrated that LTA (area under the curve [AUC]: 0.677; 95% confidence interval [CI]: 0.643-0.710; P = 0.0009), and mTEG (AUC: 0.684; 95% CI: 0.650-0.716; P = 0.0001) had moderate ability to discriminate between patients with and without MACE. MACE occurred more frequently in patients with high on-treatment platelet reactivity (HPR) when assessed by LTA (7.4% vs. 2.7%; P < 0.001), and by TEG (6.7% vs. 2.6%; P < 0.001). Kaplan-Meier analysis demonstrated that HPR based on the LTA and mTEG was associated with almost 3-fold increased risk of MACE at 1-year follow-up. Conclusions: The correlation between LTA and mTEG is relatively high in Chinese patients. HPR measured by LTA and mTEG were significantly associated with MACE in Chinese patients undergoing PCI. |
来源
|
Chinese Medical Journal
,2015,128(6):774-779 【核心库】
|
DOI
|
10.4103/0366-6999.152611
|
关键词
|
Clopidogrel
;
High On-treatment Platelet Reactivity
;
Light Transmittance Aggregometry
;
Thrombelastography
|
地址
|
1.
Department of Cardiology, Fuwai Hospital, National Centre for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, State Key Laboratory of Cardiovascular Disease, Beijing, 100037
2.
Department of Cardiology, Institute of Cardiovascular Research of People's Liberation Army, Shenyang Northern Hospital, Liaoning, Shenyang, 110840
3.
Department of Cardiology, Centre for Coronary Heart Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, State Key Laboratory of Cardiovascular Disease, Beijing, 100037
|
语种
|
英文 |
文献类型
|
研究性论文 |
ISSN
|
0366-6999 |
学科
|
内科学 |
基金
|
supported by grants from the National Research Key Project of the Twelfth Five-year Plan of Republic of China
;
国家自然科学基金
;
National Special Fund for Healthcare Research in the Public Interests of China
|
文献收藏号
|
CSCD:5363387
|
参考文献 共
27
共2页
|
1.
Mehta S R. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study.
Lancet,2001,358:527-533
|
CSCD被引
80
次
|
|
|
|
2.
Steinhubl S R. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial.
JAMA,2002,288:2411-2420
|
CSCD被引
88
次
|
|
|
|
3.
Matetzky S. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Circulation,2004,109:3171-3175
|
CSCD被引
52
次
|
|
|
|
4.
Price M J. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation.
Eur Heart J,2008,29:992-1000
|
CSCD被引
12
次
|
|
|
|
5.
Bonello L. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: A multicenter randomized prospective study.
J Am Coll Cardiol,2008,51:1404-1411
|
CSCD被引
24
次
|
|
|
|
6.
Bliden K P. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: Is the current antiplatelet therapy adequate?.
J Am Coll Cardiol,2007,49:657-666
|
CSCD被引
25
次
|
|
|
|
7.
Gurbel P A. Platelet function monitoring in patients with coronary artery disease.
J Am Coll Cardiol,2007,50:1822-1834
|
CSCD被引
30
次
|
|
|
|
8.
Bonello L. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate.
J Am Coll Cardiol,2010,56:919-933
|
CSCD被引
39
次
|
|
|
|
9.
Breet N J. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation.
JAMA,2010,303:754-762
|
CSCD被引
41
次
|
|
|
|
10.
Parodi G. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.
JAMA,2011,306:1215-1223
|
CSCD被引
10
次
|
|
|
|
11.
Gurbel P A. Platelet reactivity in patients and recurrent events post-stenting: Results of the PREPARE POST-STENTING Study.
J Am Coll Cardiol,2005,46:1820-1826
|
CSCD被引
27
次
|
|
|
|
12.
Krishna V. Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents? the role of platelet reactivity and genotype testing in the prevention of atherothrombotic cardiovascular events remains unproven.
Circulation,2012,125:1288-1303
|
CSCD被引
1
次
|
|
|
|
13.
Sibbing D. High platelet reactivity and clinical outcome-fact and fiction.
Thromb Haemost,2011,106:191-202
|
CSCD被引
3
次
|
|
|
|
14.
Kim I S. Correlation of high post-treatment platelet reactivity assessed by light transmittance aggregometry and the VerifyNow P2Y12 assay.
J Thromb Thrombolysis,2010,30:486-495
|
CSCD被引
1
次
|
|
|
|
15.
Park Y. The concordance and correlation of measurements by multiple electrode and light transmittance aggregometries based on the pre-defined cutoffs of high and low on-treatment platelet reactivity.
Platelets,2012,23:290-298
|
CSCD被引
2
次
|
|
|
|
16.
Hobson A R. A novel fifteen minute test for assessment of individual time-dependent clotting responses to aspirin and clopidogrel using modified thrombelastography.
Platelets,2007,18:497-505
|
CSCD被引
10
次
|
|
|
|
17.
Steg P G. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation.
Eur Heart J,2012,33:2569-2619
|
CSCD被引
128
次
|
|
|
|
18.
Cutlip D E. Clinical end points in coronary stent trials: A case for standardized definitions.
Circulation,2007,115:2344-2351
|
CSCD被引
170
次
|
|
|
|
19.
Hochholzer W. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement.
J Am Coll Cardiol,2006,48:1742-1750
|
CSCD被引
13
次
|
|
|
|
20.
Michelson A D. Platelet function testing in cardiovascular diseases.
Circulation,2004,110:e489-e493
|
CSCD被引
11
次
|
|
|
|
|